187P Stage I results of a phase II study of datopotamab deruxtecan (DATO-DXd) in triple-negative breast cancer (TNBC) patients (pts) with active brain metastases (TUXEDO-2)

Rupert Bartsch, Matthias Preusser, Julia Furtner et al.|ESMO Open|2024

Cited by 15